New vaccine aims to shield kids from 24 pneumonia strains

NCT ID NCT06800261

First seen Jan 31, 2026 · Last updated May 15, 2026 · Updated 11 times

Summary

This early-stage trial tests a new vaccine (PCV24) designed to protect children aged 2 to 23 months against 24 types of pneumococcal bacteria, which can cause pneumonia and other serious infections. About 180 healthy infants and toddlers will receive either the new vaccine or an existing one to compare safety and immune response. The study is double-blind, meaning neither families nor doctors know who gets which vaccine.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIOUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shandong Provincial Center for Disease Control and Prevention

    NOT_YET_RECRUITING

    Jinan, Shandong, 250014, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanxian Center for Disease Control and Prevention

    RECRUITING

    Shancheng, Shandong, 250014, China

    Contact

Conditions

Explore the condition pages connected to this study.